Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Antimicrobial Agents and Chemotherapy
|
April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers
Kelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
The Journal of Infectious Diseases
|
December 16, 2003
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion
Howard M Lederman, Paige L Williams, Julia W Wu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40
Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
AIDS Research and Human Retroviruses
|
September 1, 2005
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study
Rob Roy MacGregor, Richard Hafner, Julia W Wu, et al.
The Lancet. Infectious Diseases
|
February 15, 2021
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
Kelly E Dooley, Susan L Rosenkranz, Francesca Conradie, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial
Kamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
The Journal of Antimicrobial Chemotherapy
|
June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
The Journal of Clinical Investigation
|
May 19, 2020
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
Anca Dorhoi, Leigh A Kotzé, Jay A Berzofsky, et al.
Research Square
|
March 16, 2026
Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models
Sanjay Jain, Carlos Ruiz Gonzalez, Medha Singh, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Antimicrobial Agents and Chemotherapy
|
April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers
Kelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
The Journal of Infectious Diseases
|
December 16, 2003
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion
Howard M Lederman, Paige L Williams, Julia W Wu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2005
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40
Mitchell Goldman, Gretchen A Cloud, Karen D Wade, et al.
AIDS Research and Human Retroviruses
|
September 1, 2005
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study
Rob Roy MacGregor, Richard Hafner, Julia W Wu, et al.
The Lancet. Infectious Diseases
|
February 15, 2021
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
Kelly E Dooley, Susan L Rosenkranz, Francesca Conradie, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial
Kamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
The Journal of Antimicrobial Chemotherapy
|
June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
The Journal of Clinical Investigation
|
May 19, 2020
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
Anca Dorhoi, Leigh A Kotzé, Jay A Berzofsky, et al.
Research Square
|
March 16, 2026
Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models
Sanjay Jain, Carlos Ruiz Gonzalez, Medha Singh, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Page
of 5